Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
The University of Texas MD Anderson Cancer Center and Myriad Genetics announced a five-year strategic alliance.
-
Myriad Genetics released its Quality, Innovation, and Corporate Responsibility Report.
-
Myriad Genetics announced a MyRisk® Hereditary Cancer Test with RiskScore® study was named as one of the top 10 significant advances in genomic medicine.
-
Myriad Genetics provides update on discussions with UnitedHealthcare regarding medical policy for pharmacogenetic testing.
-
Myriad Genetics announced the election of Mark S. Davis to its Board of Director, effective immediately, expanding the Board from eight to nine members.
-
Myriad Genetics’ full suite of urologic oncology products is elevated by updated NCCN prostate cancer guidelines.
-
Myriad Genetics, Inc. announced it will present new data at the 2024 San Antonio Breast Cancer Symposium.
-
Myriad Genetics announced Prolaris prostate cancer prognostic test is classified by the NCCN as an advanced tool in the fight against prostate cancer.
-
Myriad Genetics announces incorporation of its proprietary HRD platform in Illumina’s updated comprehensive gene panel assay, TruSight™ Oncology 500 v2.
-
Myriad Genetics announced Prequel® Prenatal Screen is now available at eight weeks into pregnancy.